Moderna ( (MRNA) ) has released its Q3 earnings. Here is a breakdown of the information Moderna presented to its investors. Moderna, Inc. is a ...

MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion ...

Moderna Inc (MRNA) reports $1.9 billion in revenue and outlines future growth strategies despite competitive pressures and ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Moderna ( (MRNA)) has released its Q3 earnings. Here is a breakdown of the information Moderna presented to its investors. Moderna, Inc. is a pioneering biotechnology company specializing in the ...

Moderna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a loss of $1.89 per share. In the year-ago period, management incurred a ...